Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-214868 for idiopathic overactive bladder with urinary incontinence
NL-OMON38323Phase 2Active, not recruiting
- Sponsor
- Allergan
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in overactive bladder (OAB) comparing AGN-214868 with Placebo (2 arms). Primary endpoint: Safety profile. Started May 2011; status: active, not recruiting.
02
Drugs
senrebotase
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON38323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38323.